These results suggest that TGF-β1 may have therapeutic potential for AD by preventing excessive microglial clustering at neuritic plaques, since microglial overactivation at neuritic plaques actively contributes to neurodegeneration [32]. The gene discussed is TGFB1; the disease is Alzheimer disease.